Kite’s CAR T-Cell Therapy Yescarta®. Granted European Marketing Authorization for the Treatment of Relapsed or Refractory Follicular Lymphoma

Kite announced that the European Commission has approved its CAR T-cell therapy Yescarta® for the treatment of adult patients with relapsed or refractory follicular lymphomaafter three or more lines of systemic therapy.
Press Release

Stay up-to-date with your field!

Subscribe for free weekly science newsletters.

Related News